Genetic and Epigenetic Signatures in Acute Promyelocytic Leukemia Treatment and Molecular Remission
Acute myeloid leukemia (AML) is an aggressive, heterogeneous group of malignancies with different clinical behaviors and different responses to therapy. For many types of cancer, finding cancer early makes it easier to treat. Identifying prognostic molecular markers and understanding their biology a...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-04-01
|
| Series: | Frontiers in Genetics |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fgene.2022.821676/full |
| _version_ | 1819060331651006464 |
|---|---|
| author | Veronika Borutinskaitė Andrius Žučenka Aida Vitkevičienė Mindaugas Stoškus Algirdas Kaupinis Mindaugas Valius Eglė Gineikienė Rūta Navakauskienė |
| author_facet | Veronika Borutinskaitė Andrius Žučenka Aida Vitkevičienė Mindaugas Stoškus Algirdas Kaupinis Mindaugas Valius Eglė Gineikienė Rūta Navakauskienė |
| author_sort | Veronika Borutinskaitė |
| collection | DOAJ |
| description | Acute myeloid leukemia (AML) is an aggressive, heterogeneous group of malignancies with different clinical behaviors and different responses to therapy. For many types of cancer, finding cancer early makes it easier to treat. Identifying prognostic molecular markers and understanding their biology are the first steps toward developing novel diagnostic tools or therapies for patients with AML. In this study, we defined proteins and genes that can be used in the prognosis of different acute leukemia cases and found possible uses in diagnostics and therapy. We analyzed newly diagnosed acute leukemia cases positive for t (15; 17) (q22; q21) PML-RAR alpha, acute promyelocytic leukemia (APL). The samples of bone marrow cells were collected from patients at the diagnosis stage, as follow-up samples during standard treatment with all-trans retinoic acid, idarubicin, and mitoxantrone, and at the molecular remission. We determined changes in the expression of genes involved in leukemia cell growth, apoptosis, and differentiation. We observed that WT1, CALR, CAV1, and MYC genes’ expression in all APL patients with no relapse history was downregulated after treatment and could be potential markers associated with the pathology, thereby revealing the potential value of this approach for a better characterization of the prediction of APL outcomes. |
| first_indexed | 2024-12-21T14:25:18Z |
| format | Article |
| id | doaj.art-9d6e913bff764d9fa6f634dd55564569 |
| institution | Directory Open Access Journal |
| issn | 1664-8021 |
| language | English |
| last_indexed | 2024-12-21T14:25:18Z |
| publishDate | 2022-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Genetics |
| spelling | doaj.art-9d6e913bff764d9fa6f634dd555645692022-12-21T19:00:40ZengFrontiers Media S.A.Frontiers in Genetics1664-80212022-04-011310.3389/fgene.2022.821676821676Genetic and Epigenetic Signatures in Acute Promyelocytic Leukemia Treatment and Molecular RemissionVeronika Borutinskaitė0Andrius Žučenka1Aida Vitkevičienė2Mindaugas Stoškus3Algirdas Kaupinis4Mindaugas Valius5Eglė Gineikienė6Rūta Navakauskienė7Department of Molecular Cell Biology, Life Sciences Center, Institute of Biochemistry, Vilnius University, Vilnius, LithuaniaHematology, Oncology, and Transfusion Medicine Centre, Vilnius University Hospital Santaros Klinikos, Vilnius, LithuaniaDepartment of Molecular Cell Biology, Life Sciences Center, Institute of Biochemistry, Vilnius University, Vilnius, LithuaniaHematology, Oncology, and Transfusion Medicine Centre, Vilnius University Hospital Santaros Klinikos, Vilnius, LithuaniaProteomic Center, Life Sciences Center, Institute of Biochemistry, Vilnius University, Vilnius, LithuaniaProteomic Center, Life Sciences Center, Institute of Biochemistry, Vilnius University, Vilnius, LithuaniaHematology, Oncology, and Transfusion Medicine Centre, Vilnius University Hospital Santaros Klinikos, Vilnius, LithuaniaDepartment of Molecular Cell Biology, Life Sciences Center, Institute of Biochemistry, Vilnius University, Vilnius, LithuaniaAcute myeloid leukemia (AML) is an aggressive, heterogeneous group of malignancies with different clinical behaviors and different responses to therapy. For many types of cancer, finding cancer early makes it easier to treat. Identifying prognostic molecular markers and understanding their biology are the first steps toward developing novel diagnostic tools or therapies for patients with AML. In this study, we defined proteins and genes that can be used in the prognosis of different acute leukemia cases and found possible uses in diagnostics and therapy. We analyzed newly diagnosed acute leukemia cases positive for t (15; 17) (q22; q21) PML-RAR alpha, acute promyelocytic leukemia (APL). The samples of bone marrow cells were collected from patients at the diagnosis stage, as follow-up samples during standard treatment with all-trans retinoic acid, idarubicin, and mitoxantrone, and at the molecular remission. We determined changes in the expression of genes involved in leukemia cell growth, apoptosis, and differentiation. We observed that WT1, CALR, CAV1, and MYC genes’ expression in all APL patients with no relapse history was downregulated after treatment and could be potential markers associated with the pathology, thereby revealing the potential value of this approach for a better characterization of the prediction of APL outcomes.https://www.frontiersin.org/articles/10.3389/fgene.2022.821676/fullblastrelapsemolecular remissionepigeneticsacute promyelocytic leukemia |
| spellingShingle | Veronika Borutinskaitė Andrius Žučenka Aida Vitkevičienė Mindaugas Stoškus Algirdas Kaupinis Mindaugas Valius Eglė Gineikienė Rūta Navakauskienė Genetic and Epigenetic Signatures in Acute Promyelocytic Leukemia Treatment and Molecular Remission Frontiers in Genetics blast relapse molecular remission epigenetics acute promyelocytic leukemia |
| title | Genetic and Epigenetic Signatures in Acute Promyelocytic Leukemia Treatment and Molecular Remission |
| title_full | Genetic and Epigenetic Signatures in Acute Promyelocytic Leukemia Treatment and Molecular Remission |
| title_fullStr | Genetic and Epigenetic Signatures in Acute Promyelocytic Leukemia Treatment and Molecular Remission |
| title_full_unstemmed | Genetic and Epigenetic Signatures in Acute Promyelocytic Leukemia Treatment and Molecular Remission |
| title_short | Genetic and Epigenetic Signatures in Acute Promyelocytic Leukemia Treatment and Molecular Remission |
| title_sort | genetic and epigenetic signatures in acute promyelocytic leukemia treatment and molecular remission |
| topic | blast relapse molecular remission epigenetics acute promyelocytic leukemia |
| url | https://www.frontiersin.org/articles/10.3389/fgene.2022.821676/full |
| work_keys_str_mv | AT veronikaborutinskaite geneticandepigeneticsignaturesinacutepromyelocyticleukemiatreatmentandmolecularremission AT andriuszucenka geneticandepigeneticsignaturesinacutepromyelocyticleukemiatreatmentandmolecularremission AT aidavitkeviciene geneticandepigeneticsignaturesinacutepromyelocyticleukemiatreatmentandmolecularremission AT mindaugasstoskus geneticandepigeneticsignaturesinacutepromyelocyticleukemiatreatmentandmolecularremission AT algirdaskaupinis geneticandepigeneticsignaturesinacutepromyelocyticleukemiatreatmentandmolecularremission AT mindaugasvalius geneticandepigeneticsignaturesinacutepromyelocyticleukemiatreatmentandmolecularremission AT eglegineikiene geneticandepigeneticsignaturesinacutepromyelocyticleukemiatreatmentandmolecularremission AT rutanavakauskiene geneticandepigeneticsignaturesinacutepromyelocyticleukemiatreatmentandmolecularremission |